CN103285386A - 针对4种登革热血清型的免疫方法 - Google Patents
针对4种登革热血清型的免疫方法 Download PDFInfo
- Publication number
- CN103285386A CN103285386A CN201310128837XA CN201310128837A CN103285386A CN 103285386 A CN103285386 A CN 103285386A CN 201310128837X A CN201310128837X A CN 201310128837XA CN 201310128837 A CN201310128837 A CN 201310128837A CN 103285386 A CN103285386 A CN 103285386A
- Authority
- CN
- China
- Prior art keywords
- den
- vaccine
- dengue
- virus
- chimerivax
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012310 Dengue fever Diseases 0.000 title claims abstract description 122
- 208000025729 dengue disease Diseases 0.000 title claims abstract description 114
- 208000001490 Dengue Diseases 0.000 title claims abstract description 113
- 238000000034 method Methods 0.000 title abstract description 43
- 238000002649 immunization Methods 0.000 title description 18
- 241000700605 Viruses Species 0.000 claims description 130
- 229960005486 vaccine Drugs 0.000 claims description 119
- 229940031416 bivalent vaccine Drugs 0.000 claims description 43
- 239000000203 mixture Substances 0.000 claims description 33
- 238000012360 testing method Methods 0.000 claims description 32
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 241000725619 Dengue virus Species 0.000 abstract description 29
- 230000001939 inductive effect Effects 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 description 47
- 230000036039 immunity Effects 0.000 description 35
- 210000003484 anatomy Anatomy 0.000 description 18
- 230000003053 immunization Effects 0.000 description 17
- 241000282693 Cercopithecidae Species 0.000 description 16
- 206010058874 Viraemia Diseases 0.000 description 15
- 238000010790 dilution Methods 0.000 description 14
- 239000012895 dilution Substances 0.000 description 14
- 208000003152 Yellow Fever Diseases 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 241000615954 Varroa destructor virus-1 Species 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 230000003472 neutralizing effect Effects 0.000 description 10
- 230000003612 virological effect Effects 0.000 description 10
- 210000003501 vero cell Anatomy 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000009714 Severe Dengue Diseases 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 201000002950 dengue hemorrhagic fever Diseases 0.000 description 7
- 230000005847 immunogenicity Effects 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 241000256118 Aedes aegypti Species 0.000 description 5
- 101100112679 Caenorhabditis elegans cyd-1 gene Proteins 0.000 description 5
- 101100169267 Escherichia coli (strain K12) cydA gene Proteins 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 101710091045 Envelope protein Proteins 0.000 description 4
- 101000708009 Homo sapiens Sentrin-specific protease 8 Proteins 0.000 description 4
- 101710188315 Protein X Proteins 0.000 description 4
- 102100031407 Sentrin-specific protease 8 Human genes 0.000 description 4
- 102100021696 Syncytin-1 Human genes 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 230000002787 reinforcement Effects 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 101100169272 Escherichia coli (strain K12) cydB gene Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108091092724 Noncoding DNA Proteins 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241001536481 Banzi virus Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000710831 Flavivirus Species 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000274177 Juniperus sabina Species 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000028857 Tropical infectious disease Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- CKMXBZGNNVIXHC-UHFFFAOYSA-L ammonium magnesium phosphate hexahydrate Chemical compound [NH4+].O.O.O.O.O.O.[Mg+2].[O-]P([O-])([O-])=O CKMXBZGNNVIXHC-UHFFFAOYSA-L 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003441 anti-flavivirus Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 229940031346 monovalent vaccine Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000011330 nucleic acid test Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229910052567 struvite Inorganic materials 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940031351 tetravalent vaccine Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0608660A FR2906724B1 (fr) | 2006-10-04 | 2006-10-04 | Methode d'immunisation contre les 4 serotypes de la dengue. |
| FR0608660 | 2006-10-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007800444299A Division CN101553251B (zh) | 2006-10-04 | 2007-10-02 | 针对4种登革热血清型的免疫方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103285386A true CN103285386A (zh) | 2013-09-11 |
Family
ID=38222583
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310128837XA Pending CN103285386A (zh) | 2006-10-04 | 2007-10-02 | 针对4种登革热血清型的免疫方法 |
| CN2007800444299A Expired - Fee Related CN101553251B (zh) | 2006-10-04 | 2007-10-02 | 针对4种登革热血清型的免疫方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007800444299A Expired - Fee Related CN101553251B (zh) | 2006-10-04 | 2007-10-02 | 针对4种登革热血清型的免疫方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7718358B2 (OSRAM) |
| EP (3) | EP2077857B1 (OSRAM) |
| JP (1) | JP5269796B2 (OSRAM) |
| KR (1) | KR20090064593A (OSRAM) |
| CN (2) | CN103285386A (OSRAM) |
| AR (1) | AR063057A1 (OSRAM) |
| AU (1) | AU2007311792B2 (OSRAM) |
| BR (1) | BRPI0719849A2 (OSRAM) |
| CA (1) | CA2663885A1 (OSRAM) |
| FR (1) | FR2906724B1 (OSRAM) |
| IL (2) | IL197768A0 (OSRAM) |
| MX (1) | MX2009003417A (OSRAM) |
| TW (2) | TW201336508A (OSRAM) |
| WO (1) | WO2008047023A2 (OSRAM) |
| ZA (1) | ZA200901816B (OSRAM) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108699534A (zh) * | 2015-11-27 | 2018-10-23 | 般财团法人化学及血清疗法研究所 | 具有登革热病毒减毒株库的活病毒和包含其作为抗原的登革热疫苗 |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1924280A4 (en) * | 2005-08-10 | 2008-12-10 | Acambis Inc | VACCINATION AGAINST DENGUE VIRUS INFECTION |
| FR2903605A1 (fr) * | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
| FR2909286B1 (fr) * | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
| ES2615390T3 (es) | 2008-03-05 | 2017-06-06 | Sanofi Pasteur | Proceso para estabilizar una composición de vacuna que contiene adyuvante |
| EP2143440A1 (fr) * | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
| US8968996B2 (en) | 2009-06-01 | 2015-03-03 | Takeda Vaccines, Inc. | Compositions and methods for rapid immunization against dengue virus |
| US9211323B2 (en) | 2009-06-01 | 2015-12-15 | Takeda Vaccines, Inc. | Compositions and methods for administration of vaccines against dengue virus |
| WO2011026139A1 (en) | 2009-08-31 | 2011-03-03 | Gen-Probe Incorporated | Dengue virus assay |
| EP2353609A1 (en) * | 2010-02-04 | 2011-08-10 | Sanofi Pasteur | Immunization compositions and methods |
| US10238734B2 (en) | 2010-03-23 | 2019-03-26 | The Regents Of The University Of California | Compositions and methods for self-adjuvanting vaccines against microbes and tumors |
| WO2013003579A1 (en) * | 2011-06-29 | 2013-01-03 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of dengue virus infection |
| EP2858668A1 (en) * | 2012-06-10 | 2015-04-15 | Takeda Vaccines, Inc. | Compositions and methods for administration of vaccines against dengue virus |
| US8895028B2 (en) * | 2012-07-20 | 2014-11-25 | Arbovax, Inc. | Methods and compositions for dengue virus 3 (DV3) infectious clone |
| MY168959A (en) | 2012-07-24 | 2019-01-28 | Sanofi Pasteur | Vaccine compositions for the prevention of dengue virus infection |
| CA2878599A1 (en) | 2012-07-24 | 2014-01-30 | Jiansheng Yao | Vaccine compositions for prevention against dengue virus infection |
| BR112015012515B1 (pt) | 2012-11-30 | 2023-04-11 | Sanofi Pasteur | Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola |
| JP2016504315A (ja) * | 2012-12-14 | 2016-02-12 | タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. | 三価デングウイルス製剤に関する組成物、投与方法および使用 |
| MX366154B (es) | 2013-06-21 | 2019-06-28 | Merck Sharp & Dohme | Composiciones de vacuna del virus del dengue y metodos de uso de las mismas. |
| TWI852899B (zh) | 2014-09-02 | 2024-08-21 | 法商賽諾菲巴斯德公司 | 疫苗組合物 |
| MY192543A (en) | 2014-12-22 | 2022-08-26 | Merck Sharp & Dohme | Dengue virus vaccine compositions and methods of use thereof |
| US10857222B2 (en) | 2015-07-03 | 2020-12-08 | Sanofi Pasteur | Concomitant dengue and yellow fever vaccination |
| AU2018346724B2 (en) | 2017-10-05 | 2025-01-09 | Sanofi Pasteur | Compositions for booster vaccination against dengue |
| CN112912106A (zh) | 2018-09-05 | 2021-06-04 | 武田疫苗股份有限公司 | 登革热疫苗单位剂量及其施用 |
| MX2022001742A (es) | 2019-08-16 | 2022-04-07 | Takeda Vaccines Inc | Metodos para prevenir el dengue y la hepatitis a. |
| EP4110381A1 (en) | 2020-02-27 | 2023-01-04 | Takeda Vaccines, Inc. | Method for removing host cell dna from virus preparation |
| WO2023147342A2 (en) | 2022-01-25 | 2023-08-03 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
| WO2023158989A1 (en) | 2022-02-15 | 2023-08-24 | Takeda Vaccines, Inc. | Dengue vaccine batch mixing process |
| EP4519847A1 (en) | 2022-05-04 | 2025-03-12 | Takeda Vaccines, Inc. | Computer-based determination of flavivirus infectivity |
| CN120225693A (zh) | 2022-11-18 | 2025-06-27 | 武田疫苗股份有限公司 | 测定制剂中具有包含至少一个减毒基因座的核苷酸序列的活减毒黄病毒的比例的方法 |
| CN120529951A (zh) | 2022-11-29 | 2025-08-22 | 武田疫苗股份有限公司 | 大规模黄病毒疫苗生产和制造 |
| WO2025072259A1 (en) | 2023-09-25 | 2025-04-03 | Takeda Vaccines, Inc. | Coadministration of tetravalent dengue vaccine with hpv vaccine |
| WO2025122855A1 (en) | 2023-12-08 | 2025-06-12 | Takeda Vaccines, Inc. | A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6093296A (en) | 1995-06-07 | 1996-12-30 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Infectious dengue 2 virus pdk-53 as quadravalent vaccine |
| CA2282790C (en) | 1997-02-28 | 2011-04-19 | St. Louis University | Chimeric flavivirus vaccines |
| WO1999061916A1 (en) | 1998-05-29 | 1999-12-02 | Epimmune, Inc. | Identification of broadly reactive dr restricted epitopes |
| AU4179200A (en) | 1999-03-26 | 2000-10-16 | Walter Reed Army Institute Of Research | Attenuated dengue-1 virus vaccine |
| CA2365411A1 (en) | 1999-03-26 | 2000-10-05 | Walter Reed Army Institute Of Research | Attenuated dengue-2 virus vaccine |
| CA2368790A1 (en) | 1999-03-26 | 2000-10-05 | Walter Reed Army Institute Of Research | Attenuated dengue-3 virus vaccine |
| US6537557B1 (en) * | 1999-03-26 | 2003-03-25 | The United States Of America As Represented By The Secretary Of The Army | Attenuated dengue-4 virus vaccine |
| AU779280B2 (en) * | 1999-03-26 | 2005-01-13 | Walter Reed Army Institute Of Research | Multivalent dengue virus vaccine |
| US6632663B1 (en) | 1999-09-22 | 2003-10-14 | Aventis Pasteur Limited | DNA immunization against chlamydia infection |
| CA2941182A1 (en) | 2000-02-16 | 2001-08-23 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Avirulent, immunogenic flavivirus chimeras |
| EP1159969A1 (fr) | 2000-05-30 | 2001-12-05 | Aventis Pasteur | Vaccine composition |
| PT1159968E (pt) * | 2000-05-30 | 2008-11-20 | Univ Mahidol | Estirpes atenuadas de vírus do dengue e a sua utilização numa composição de vacina |
| AT410634B (de) | 2001-02-21 | 2003-06-25 | Franz X Dr Heinz | Attenuierte lebendimpfstoffe |
| EP1402075B1 (en) | 2001-05-22 | 2012-11-14 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, the Department of Health and Human Services, | Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses |
| WO2002095007A2 (en) | 2001-05-23 | 2002-11-28 | Dendreon San Diego Llc | Conjugates activated by cell surface proteases and therapeutic uses thereof |
| PL371187A1 (en) | 2001-06-01 | 2005-06-13 | Acambis, Inc. | Chimeric flavivirus vectors |
| US20040120964A1 (en) * | 2001-10-29 | 2004-06-24 | Mikszta John A. | Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses |
| JP2005519639A (ja) * | 2002-01-15 | 2005-07-07 | アカンビス インコーポレーティッド | フラビウイルスワクチン |
| AU2003239932A1 (en) * | 2002-05-31 | 2003-12-19 | Acambis, Inc. | Tetravalent dengue vaccines |
| BRPI0408774A (pt) * | 2003-03-24 | 2006-03-28 | Scripps Research Inst | vacinas de dna contra crescimento tumoral e seus usos |
| WO2006134433A1 (en) * | 2005-06-17 | 2006-12-21 | Sanofi Pasteur | Dengue serotype 1 attenuated strain |
| EP1924280A4 (en) * | 2005-08-10 | 2008-12-10 | Acambis Inc | VACCINATION AGAINST DENGUE VIRUS INFECTION |
| FR2903605A1 (fr) * | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
| FR2909286B1 (fr) * | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
-
2006
- 2006-10-04 FR FR0608660A patent/FR2906724B1/fr not_active Expired - Fee Related
-
2007
- 2007-09-20 TW TW102119488A patent/TW201336508A/zh unknown
- 2007-09-20 TW TW096135167A patent/TWI406673B/zh not_active IP Right Cessation
- 2007-09-28 AR ARP070104316A patent/AR063057A1/es unknown
- 2007-10-02 WO PCT/FR2007/052054 patent/WO2008047023A2/fr not_active Ceased
- 2007-10-02 CN CN201310128837XA patent/CN103285386A/zh active Pending
- 2007-10-02 BR BRPI0719849-3A2A patent/BRPI0719849A2/pt active Search and Examination
- 2007-10-02 US US11/866,382 patent/US7718358B2/en not_active Expired - Fee Related
- 2007-10-02 CA CA002663885A patent/CA2663885A1/en not_active Abandoned
- 2007-10-02 KR KR1020097008657A patent/KR20090064593A/ko not_active Abandoned
- 2007-10-02 JP JP2009530916A patent/JP5269796B2/ja not_active Expired - Fee Related
- 2007-10-02 MX MX2009003417A patent/MX2009003417A/es active IP Right Grant
- 2007-10-02 ZA ZA200901816A patent/ZA200901816B/xx unknown
- 2007-10-02 CN CN2007800444299A patent/CN101553251B/zh not_active Expired - Fee Related
- 2007-10-02 AU AU2007311792A patent/AU2007311792B2/en not_active Ceased
- 2007-10-02 EP EP07858487.7A patent/EP2077857B1/fr not_active Not-in-force
- 2007-10-02 EP EP11192672A patent/EP2526965A1/fr not_active Withdrawn
- 2007-10-02 EP EP11192665A patent/EP2526964A1/fr not_active Withdrawn
-
2009
- 2009-03-23 IL IL197768A patent/IL197768A0/en not_active IP Right Cessation
-
2010
- 2010-03-05 US US12/718,308 patent/US20100270202A1/en not_active Abandoned
-
2013
- 2013-02-04 IL IL224572A patent/IL224572A/en not_active IP Right Cessation
Non-Patent Citations (2)
| Title |
|---|
| F.GUIRAKHOO 等: "Construction，Safty，and Immunogenicity in Nonhuman Primates of chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine", <JOURNAL OF VIROLOGY> * |
| N. BHAMARAPRAVATI等: "Live attenuated tetravalent dengue vaccine", <VACCINE> * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108699534A (zh) * | 2015-11-27 | 2018-10-23 | 般财团法人化学及血清疗法研究所 | 具有登革热病毒减毒株库的活病毒和包含其作为抗原的登革热疫苗 |
| CN108699534B (zh) * | 2015-11-27 | 2022-05-24 | Km生物医药股份公司 | 具有登革热病毒减毒株库的活病毒和包含其作为抗原的登革热疫苗 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007311792A1 (en) | 2008-04-24 |
| EP2526965A1 (fr) | 2012-11-28 |
| JP5269796B2 (ja) | 2013-08-21 |
| TWI406673B (zh) | 2013-09-01 |
| ZA200901816B (en) | 2010-06-30 |
| AR063057A1 (es) | 2008-12-23 |
| WO2008047023A2 (fr) | 2008-04-24 |
| US20080085288A1 (en) | 2008-04-10 |
| EP2526964A1 (fr) | 2012-11-28 |
| KR20090064593A (ko) | 2009-06-19 |
| EP2077857A2 (fr) | 2009-07-15 |
| FR2906724B1 (fr) | 2009-03-20 |
| AU2007311792B2 (en) | 2013-05-02 |
| TW200826959A (en) | 2008-07-01 |
| MX2009003417A (es) | 2009-04-09 |
| CN101553251B (zh) | 2013-05-22 |
| IL197768A0 (en) | 2011-08-01 |
| FR2906724A1 (fr) | 2008-04-11 |
| US20100270202A1 (en) | 2010-10-28 |
| BRPI0719849A2 (pt) | 2014-04-29 |
| EP2077857B1 (fr) | 2013-11-20 |
| US7718358B2 (en) | 2010-05-18 |
| IL224572A (en) | 2014-06-30 |
| CN101553251A (zh) | 2009-10-07 |
| CA2663885A1 (en) | 2008-04-24 |
| WO2008047023A3 (fr) | 2008-10-23 |
| TW201336508A (zh) | 2013-09-16 |
| JP2010505801A (ja) | 2010-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101553251B (zh) | 针对4种登革热血清型的免疫方法 | |
| CN101489585B (zh) | 针对登革病毒四种血清型的免疫接种方法 | |
| AU2007327367B2 (en) | Immunization protocol against the 4 dengue serotypes | |
| US8067566B2 (en) | Dengue serotype 2 attenuated strain | |
| KR101464649B1 (ko) | 약독화된 뎅기 혈청형 1 균주 | |
| US20130095136A1 (en) | Tetravalent Dengue Vaccines | |
| Zhang et al. | Long-term passage of duck Tembusu virus in BHK-21 cells generates a completely attenuated and immunogenic population with increased genetic diversity | |
| Le et al. | Pathologic potential of variant clones of the oshima strain of far-eastern subtype tick-borne encephalitis virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130911 |
|
| RJ01 | Rejection of invention patent application after publication |